Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
25
QURE Quote, Financials, Valuation and Earnings
Last price:
$15.75
Seasonality move
:
0.95%
Day range:
$16.21 - $21.07
52-week range:
$7.76 - $71.50
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
58.48x
P/B ratio:
4.66x
Volume:
17.7M
Avg. volume:
2.4M
1-year change:
46.66%
Market cap:
$1.1B
Revenue:
$27.1M
EPS (TTM):
-$4.39
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
QURE
uniQure NV
|
$5.6M | -$0.93 | 339.4% | -13.99% | $53.52 |
|
ARGX
argenx SE
|
$1.3B | $6.19 | 87.13% | 205.62% | $1,031.68 |
|
NAMS
NewAmsterdam Pharma Co. NV
|
$2.9M | -$0.43 | -60.56% | -48.71% | $48.95 |
|
PHAR
Pharming Group NV
|
$106.1M | $0.01 | 17.76% | -100% | $31.00 |
|
PHVS
Pharvaris NV
|
-- | -$0.72 | -- | -15.87% | $46.30 |
|
PRQR
ProQR Therapeutics NV
|
$6.1M | -$0.17 | 17.05% | -55.96% | $8.88 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
QURE
uniQure NV
|
$17.12 | $53.52 | $1.1B | -- | $0.00 | 0% | 58.48x |
|
ARGX
argenx SE
|
$771.53 | $1,031.68 | $47.7B | 42.59x | $0.00 | 0% | 16.45x |
|
NAMS
NewAmsterdam Pharma Co. NV
|
$34.28 | $48.95 | $3.9B | -- | $0.00 | 0% | 178.26x |
|
PHAR
Pharming Group NV
|
$16.37 | $31.00 | $1.1B | 1,144.76x | $0.00 | 0% | 3.08x |
|
PHVS
Pharvaris NV
|
$28.00 | $46.30 | $1.8B | -- | $0.00 | 0% | -- |
|
PRQR
ProQR Therapeutics NV
|
$1.59 | $8.88 | $167.5M | -- | $0.00 | 0% | 9.62x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
QURE
uniQure NV
|
69.92% | 7.217 | 14.65% | 6.94x |
|
ARGX
argenx SE
|
-- | 0.022 | -- | 4.92x |
|
NAMS
NewAmsterdam Pharma Co. NV
|
0.03% | 1.199 | 0.01% | 7.43x |
|
PHAR
Pharming Group NV
|
33.1% | 0.932 | 13.18% | 2.39x |
|
PHVS
Pharvaris NV
|
0.19% | -0.126 | 0.04% | 12.56x |
|
PRQR
ProQR Therapeutics NV
|
20.36% | 3.348 | 7.64% | 3.23x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
QURE
uniQure NV
|
-$329K | -$50.7M | -40.98% | -382.35% | -1370.5% | -$17.7M |
|
ARGX
argenx SE
|
$837.2M | $203.8M | 24.23% | 28.06% | 30.38% | $312.8M |
|
NAMS
NewAmsterdam Pharma Co. NV
|
-$27K | -$66M | -27.35% | -27.36% | -206187.5% | -$41M |
|
PHAR
Pharming Group NV
|
$89.8M | $15.8M | 0.25% | 0.39% | 16.34% | $29.9M |
|
PHVS
Pharvaris NV
|
-$122.9K | -$46.3M | -62.86% | -63% | -- | -$38.2M |
|
PRQR
ProQR Therapeutics NV
|
$2.6M | -$13.2M | -54.22% | -67.34% | -392.68% | -$15.4M |
uniQure NV vs. Competitors
-
Which has Higher Returns QURE or ARGX?
argenx SE has a net margin of -2175.87% compared to uniQure NV's net margin of 25.88%. uniQure NV's return on equity of -382.35% beat argenx SE's return on equity of 28.06%.
Company Gross Margin Earnings Per Share Invested Capital QUREuniQure NV-8.89% -$1.38 $760.4M ARGXargenx SE88.32% $3.74 $6.1B -
What do Analysts Say About QURE or ARGX?
uniQure NV has a consensus price target of $53.52, signalling upside risk potential of 212.7%. On the other hand argenx SE has an analysts' consensus of $1,031.68 which suggests that it could grow by 33.72%. Given that uniQure NV has higher upside potential than argenx SE, analysts believe uniQure NV is more attractive than argenx SE.
Company Buy Ratings Hold Ratings Sell Ratings QUREuniQure NV9 4 0 ARGXargenx SE15 1 0 -
Is QURE or ARGX More Risky?
uniQure NV has a beta of 0.663, which suggesting that the stock is 33.669% less volatile than S&P 500. In comparison argenx SE has a beta of 0.374, suggesting its less volatile than the S&P 500 by 62.596%.
-
Which is a Better Dividend Stock QURE or ARGX?
uniQure NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. argenx SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. uniQure NV pays -- of its earnings as a dividend. argenx SE pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios QURE or ARGX?
uniQure NV quarterly revenues are $3.7M, which are smaller than argenx SE quarterly revenues of $948M. uniQure NV's net income of -$80.5M is lower than argenx SE's net income of $245.4M. Notably, uniQure NV's price-to-earnings ratio is -- while argenx SE's PE ratio is 42.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for uniQure NV is 58.48x versus 16.45x for argenx SE. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income QUREuniQure NV58.48x -- $3.7M -$80.5M ARGXargenx SE16.45x 42.59x $948M $245.4M
-
Which has Higher Returns QURE or NAMS?
NewAmsterdam Pharma Co. NV has a net margin of -2175.87% compared to uniQure NV's net margin of -234134.38%. uniQure NV's return on equity of -382.35% beat NewAmsterdam Pharma Co. NV's return on equity of -27.36%.
Company Gross Margin Earnings Per Share Invested Capital QUREuniQure NV-8.89% -$1.38 $760.4M NAMSNewAmsterdam Pharma Co. NV-84.38% -$0.65 $683.6M -
What do Analysts Say About QURE or NAMS?
uniQure NV has a consensus price target of $53.52, signalling upside risk potential of 212.7%. On the other hand NewAmsterdam Pharma Co. NV has an analysts' consensus of $48.95 which suggests that it could grow by 42.81%. Given that uniQure NV has higher upside potential than NewAmsterdam Pharma Co. NV, analysts believe uniQure NV is more attractive than NewAmsterdam Pharma Co. NV.
Company Buy Ratings Hold Ratings Sell Ratings QUREuniQure NV9 4 0 NAMSNewAmsterdam Pharma Co. NV10 1 0 -
Is QURE or NAMS More Risky?
uniQure NV has a beta of 0.663, which suggesting that the stock is 33.669% less volatile than S&P 500. In comparison NewAmsterdam Pharma Co. NV has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock QURE or NAMS?
uniQure NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NewAmsterdam Pharma Co. NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. uniQure NV pays -- of its earnings as a dividend. NewAmsterdam Pharma Co. NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios QURE or NAMS?
uniQure NV quarterly revenues are $3.7M, which are larger than NewAmsterdam Pharma Co. NV quarterly revenues of $32K. uniQure NV's net income of -$80.5M is lower than NewAmsterdam Pharma Co. NV's net income of -$74.9M. Notably, uniQure NV's price-to-earnings ratio is -- while NewAmsterdam Pharma Co. NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for uniQure NV is 58.48x versus 178.26x for NewAmsterdam Pharma Co. NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income QUREuniQure NV58.48x -- $3.7M -$80.5M NAMSNewAmsterdam Pharma Co. NV178.26x -- $32K -$74.9M
-
Which has Higher Returns QURE or PHAR?
Pharming Group NV has a net margin of -2175.87% compared to uniQure NV's net margin of 7.71%. uniQure NV's return on equity of -382.35% beat Pharming Group NV's return on equity of 0.39%.
Company Gross Margin Earnings Per Share Invested Capital QUREuniQure NV-8.89% -$1.38 $760.4M PHARPharming Group NV92.7% $0.11 $395.6M -
What do Analysts Say About QURE or PHAR?
uniQure NV has a consensus price target of $53.52, signalling upside risk potential of 212.7%. On the other hand Pharming Group NV has an analysts' consensus of $31.00 which suggests that it could grow by 89.37%. Given that uniQure NV has higher upside potential than Pharming Group NV, analysts believe uniQure NV is more attractive than Pharming Group NV.
Company Buy Ratings Hold Ratings Sell Ratings QUREuniQure NV9 4 0 PHARPharming Group NV3 0 0 -
Is QURE or PHAR More Risky?
uniQure NV has a beta of 0.663, which suggesting that the stock is 33.669% less volatile than S&P 500. In comparison Pharming Group NV has a beta of -0.009, suggesting its less volatile than the S&P 500 by 100.89%.
-
Which is a Better Dividend Stock QURE or PHAR?
uniQure NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pharming Group NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. uniQure NV pays -- of its earnings as a dividend. Pharming Group NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios QURE or PHAR?
uniQure NV quarterly revenues are $3.7M, which are smaller than Pharming Group NV quarterly revenues of $96.9M. uniQure NV's net income of -$80.5M is lower than Pharming Group NV's net income of $7.5M. Notably, uniQure NV's price-to-earnings ratio is -- while Pharming Group NV's PE ratio is 1,144.76x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for uniQure NV is 58.48x versus 3.08x for Pharming Group NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income QUREuniQure NV58.48x -- $3.7M -$80.5M PHARPharming Group NV3.08x 1,144.76x $96.9M $7.5M
-
Which has Higher Returns QURE or PHVS?
Pharvaris NV has a net margin of -2175.87% compared to uniQure NV's net margin of --. uniQure NV's return on equity of -382.35% beat Pharvaris NV's return on equity of -63%.
Company Gross Margin Earnings Per Share Invested Capital QUREuniQure NV-8.89% -$1.38 $760.4M PHVSPharvaris NV-- -$0.70 $367.6M -
What do Analysts Say About QURE or PHVS?
uniQure NV has a consensus price target of $53.52, signalling upside risk potential of 212.7%. On the other hand Pharvaris NV has an analysts' consensus of $46.30 which suggests that it could grow by 65.34%. Given that uniQure NV has higher upside potential than Pharvaris NV, analysts believe uniQure NV is more attractive than Pharvaris NV.
Company Buy Ratings Hold Ratings Sell Ratings QUREuniQure NV9 4 0 PHVSPharvaris NV8 1 0 -
Is QURE or PHVS More Risky?
uniQure NV has a beta of 0.663, which suggesting that the stock is 33.669% less volatile than S&P 500. In comparison Pharvaris NV has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock QURE or PHVS?
uniQure NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pharvaris NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. uniQure NV pays -- of its earnings as a dividend. Pharvaris NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios QURE or PHVS?
uniQure NV quarterly revenues are $3.7M, which are larger than Pharvaris NV quarterly revenues of --. uniQure NV's net income of -$80.5M is lower than Pharvaris NV's net income of -$43.4M. Notably, uniQure NV's price-to-earnings ratio is -- while Pharvaris NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for uniQure NV is 58.48x versus -- for Pharvaris NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income QUREuniQure NV58.48x -- $3.7M -$80.5M PHVSPharvaris NV-- -- -- -$43.4M
-
Which has Higher Returns QURE or PRQR?
ProQR Therapeutics NV has a net margin of -2175.87% compared to uniQure NV's net margin of -381.88%. uniQure NV's return on equity of -382.35% beat ProQR Therapeutics NV's return on equity of -67.34%.
Company Gross Margin Earnings Per Share Invested Capital QUREuniQure NV-8.89% -$1.38 $760.4M PRQRProQR Therapeutics NV76.72% -$0.12 $84.2M -
What do Analysts Say About QURE or PRQR?
uniQure NV has a consensus price target of $53.52, signalling upside risk potential of 212.7%. On the other hand ProQR Therapeutics NV has an analysts' consensus of $8.88 which suggests that it could grow by 458.18%. Given that ProQR Therapeutics NV has higher upside potential than uniQure NV, analysts believe ProQR Therapeutics NV is more attractive than uniQure NV.
Company Buy Ratings Hold Ratings Sell Ratings QUREuniQure NV9 4 0 PRQRProQR Therapeutics NV7 0 0 -
Is QURE or PRQR More Risky?
uniQure NV has a beta of 0.663, which suggesting that the stock is 33.669% less volatile than S&P 500. In comparison ProQR Therapeutics NV has a beta of 0.200, suggesting its less volatile than the S&P 500 by 79.991%.
-
Which is a Better Dividend Stock QURE or PRQR?
uniQure NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProQR Therapeutics NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. uniQure NV pays -- of its earnings as a dividend. ProQR Therapeutics NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios QURE or PRQR?
uniQure NV quarterly revenues are $3.7M, which are larger than ProQR Therapeutics NV quarterly revenues of $3.4M. uniQure NV's net income of -$80.5M is lower than ProQR Therapeutics NV's net income of -$12.9M. Notably, uniQure NV's price-to-earnings ratio is -- while ProQR Therapeutics NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for uniQure NV is 58.48x versus 9.62x for ProQR Therapeutics NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income QUREuniQure NV58.48x -- $3.7M -$80.5M PRQRProQR Therapeutics NV9.62x -- $3.4M -$12.9M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
50
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 38x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Sell
37
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
59
SEZL alert for Feb 27
Sezzle, Inc. [SEZL] is down 14.29% over the past day.
Buy
83
GCT alert for Feb 27
GigaCloud Technology, Inc. [GCT] is down 7.51% over the past day.
Buy
62
LMAT alert for Feb 27
LeMaitre Vascular, Inc. [LMAT] is down 5.73% over the past day.
